Latest & greatest articles for type 2 diabetes

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on type 2 diabetes or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on type 2 diabetes and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for type 2 diabetes

1. Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial

Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set (...) options Format Share Permalink Copy Page navigation Randomized Controlled Trial Lancet Diabetes Endocrinol Actions . 2020 Dec;8(12):949-959. doi: 10.1016/S2213-8587(20)30344-2. Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Division of Cardiology, Department of Internal Medicine, University

2020 EvidenceUpdates

2. Impact of Ramadan-focused diabetes education on hypoglycemia risk and metabolic control for patients with type 2 diabetes mellitus: A systematic review

Impact of Ramadan-focused diabetes education on hypoglycemia risk and metabolic control for patients with type 2 diabetes mellitus: A systematic review Impact of Ramadan-focused diabetes education on hypoglycemia risk and metabolic control for patients with type 2 diabetes mellitus: A systematic review - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features (...) Actions . 2020 Nov 7;e13817. doi: 10.1111/ijcp.13817. Online ahead of print. Impact of Ramadan-focused diabetes education on hypoglycemia risk and metabolic control for patients with type 2 diabetes mellitus: A systematic review , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Chronic Diseases Center, Family and Community Medicine Department, Prince Sultan Military Medical City, Riyadh, Saudi Arabia. 2 Department of Data Science, King Hussein Faculty for Computer Sciences, Princess

2020 EvidenceUpdates

3. Within-Trial Cost-Effectiveness of a Structured Lifestyle Intervention in Adults With Overweight/Obesity and Type 2 Diabetes: Results From the Action for Health in Diabetes (Look AHEAD) Study

Within-Trial Cost-Effectiveness of a Structured Lifestyle Intervention in Adults With Overweight/Obesity and Type 2 Diabetes: Results From the Action for Health in Diabetes (Look AHEAD) Study Within-Trial Cost-Effectiveness of a Structured Lifestyle Intervention in Adults With Overweight/Obesity and Type 2 Diabetes: Results From the Action for Health in Diabetes (Look AHEAD) Study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set (...) options Format Share Permalink Copy Page navigation Diabetes Care Actions . 2020 Nov 9;dc200358. doi: 10.2337/dc20-0358. Online ahead of print. Within-Trial Cost-Effectiveness of a Structured Lifestyle Intervention in Adults With Overweight/Obesity and Type 2 Diabetes: Results From the Action for Health in Diabetes (Look AHEAD) Study , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Centers for Disease Control and Prevention, Atlanta

2020 EvidenceUpdates

4. Development of a hypoglycaemia risk score to identify high-risk individuals with advanced type 2 diabetes in DEVOTE Full Text available with Trip Pro

Development of a hypoglycaemia risk score to identify high-risk individuals with advanced type 2 diabetes in DEVOTE Development of a hypoglycaemia risk score to identify high-risk individuals with advanced type 2 diabetes in DEVOTE - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation (...) risk score to identify high-risk individuals with advanced type 2 diabetes in DEVOTE , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK. 2 Department of Internal Medicine and Department of Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas, Texas, USA. 3 HCA Midwest Health Heart and Vascular Institute, Overland Park, Kansas, USA. 4 Scripps Whittier Diabetes Institute, San Diego

2020 EvidenceUpdates

5. The impact of pharmacological and lifestyle interventions on body weight in people with type 1 diabetes: A systematic review and meta-analysis Full Text available with Trip Pro

/dom.14221. Online ahead of print. The impact of pharmacological and lifestyle interventions on body weight in people with type 1 diabetes: A systematic review and meta-analysis , , , , Affiliations Expand Affiliations 1 School of Population Health and Environmental Sciences, Faculty of Life Sciences and Medicine, King's College London, London, UK. 2 Institute of Diabetes Endocrinology and Obesity, King's Health Partners, London, UK. 3 Diabetes Research Group, Weston Education Centre, King's (...) : Item in Clipboard Full-text links Cite Display options Display options Format Abstract Aim: To systematically review the effects of pharmacological and lifestyle interventions on body weight as a secondary outcome in people with type 1 diabetes. Methods: The Ovid Medline, Embase and Cochrane Library databases were searched for relevant pharmacological (glucagon-like peptide-1 [GLP-1] receptor agonist, sodium-glucose co-transporter-2 [SGLT-2] inhibitor, dipeptidyl peptidase-4 [DPP-4] inhibitor

2020 EvidenceUpdates

6. A duodenal sleeve bypass device added to intensive medical therapy for obesity with type 2 diabetes: a RCT Full Text available with Trip Pro

A duodenal sleeve bypass device added to intensive medical therapy for obesity with type 2 diabetes: a RCT A duodenal sleeve bypass device added to intensive medical therapy for obesity with type 2 diabetes: a RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need (...) , Ghadah Aldubaikhi 4 , Ben Glover 1 , Joanne Lord 6 , Olu Onyimadu 6 , Emmanuela Falaschetti 5 , Natalia Klimowska-Nassar 5 , Hutan Ashrafian 1 , James Byrne 7 , Julian P Teare 1 1 Department of Surgery and Cancer, St Mary’s Hospital, Imperial College London, London, UK 2 National Institute for Health Research Southampton Biomedical Research Centre, Southampton Centre for Biomedical Research, Southampton General Hospital, Southampton, UK 3 Section of Investigative Medicine, Division of Diabetes

2020 NIHR HTA programme

7. Continuous glucose monitoring in pregnant women with type 1 diabetes

for NHSScotland. Epidemiology and predicted volume According to Diabetes UK, 5% of the 956,861 pregnancies in the UK in 2015 involved diabetes: ? 42,000 involved gestational diabetes (87.5%) ? 3,600 involved T1DM (7.5%) ? 2,400 involved type 2 diabetes (5%) 2 The number of women in Scotland with T1DM who became pregnant rose from 205 in 1998/99 to 264 in 2012/13 3 . Scottish context The Scottish Intercollegiate Guidelines Network (SIGN) guideline on The Management of Diabetes (published in 2010 and updated (...) in 2017 with the section on pregnancy currently being reviewed) includes a recommendation that: “Continuous glucose monitoring may be considered in women with type 1 and type 2 diabetes.” In June 2017, the Scottish Government wrote to Health Boards announcing £10m funding over 5 years to increase insulin pump use and encourage the implementation of CGM systems 4 . In a Scottish Government letter dated July 2019, those considered highest priority for commencement of CGM included pregnant women

2020 SHTG Advice Statements

8. Comprehensive Type 2 Diabetes Management Algorithm

Comprehensive Type 2 Diabetes Management Algorithm ENDOCRINE PRACTICE Vol 26 No. 1 January 2020 107 CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM – 2020 EXECUTIVE SUMMARY Alan J. Garber, MD, PhD, MACE 1 ; Yehuda Handelsman, MD, FACP , FNLA, MACE 2 ; George Grunberger, MD, FACP , FACE 3 ; Daniel Einhorn, MD, FACP , FACE 4 ; Martin J. Abrahamson, MD 5 ; Joshua I. Barzilay (...) trial; SU = sulfonylurea; SGLT2 = sodium-glucose cotransporter 2; SMBG = self-moni- toring of blood glucose; T2D = type 2 diabetes; TZD = thiazolidinedione EXECUTIVE SUMMARY This algorithm for the comprehensive management of persons with type 2 diabetes (T2D) was developed to provide clinicians with a practical guide that considers the whole patient, his or her spectrum of risks and complica- tions, and evidence-based approaches to treatment. It is now clear that the progressive pancreatic beta-cell

2020 American Association of Clinical Endocrinologists

9. An Early-Onset Subgroup of Type 2 Diabetes: A Multigenerational, Prospective Analysis in the Framingham Heart Study

An Early-Onset Subgroup of Type 2 Diabetes: A Multigenerational, Prospective Analysis in the Framingham Heart Study An Early-Onset Subgroup of Type 2 Diabetes: A Multigenerational, Prospective Analysis in the Framingham Heart Study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation (...) Subgroup of Type 2 Diabetes: A Multigenerational, Prospective Analysis in the Framingham Heart Study , , , , , , , Affiliations Expand Affiliations 1 Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Johns Hopkins University, Baltimore, MD jechouf1@jhmi.edu. 2 Department of Medicine, Turku University Hospital and University of Turku, Turku, Finland. 3 Department of Biostatistics, Boston University School of Public Health, Boston, MA. 4 Division of Cardiovascular Medicine

2020 EvidenceUpdates

10. Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study Full Text available with Trip Pro

Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study - PubMed This site needs JavaScript (...) RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Diabetes Obes Metab Actions . 2020 Sep 7. doi: 10.1111/dom.14189. Online ahead of print. Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Oslo

2020 EvidenceUpdates

11. Efficacy and safety of polyethylene glycol loxenatide (PEX168) monotherapy in type 2 diabetes patients: a multicenter, randomized, double-blind, placebo-controlled, phase 3a clinical trial. Full Text available with Trip Pro

Efficacy and safety of polyethylene glycol loxenatide (PEX168) monotherapy in type 2 diabetes patients: a multicenter, randomized, double-blind, placebo-controlled, phase 3a clinical trial. Efficacy and safety of polyethylene glycol loxenatide monotherapy in type 2 diabetes patients: A multicentre, randomized, double-blind, placebo-controlled phase 3a clinical trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features (...) Share Permalink Copy Page navigation Diabetes Obes Metab Actions . 2020 Sep 23. doi: 10.1111/dom.14198. Online ahead of print. Efficacy and safety of polyethylene glycol loxenatide monotherapy in type 2 diabetes patients: A multicentre, randomized, double-blind, placebo-controlled phase 3a clinical trial , , , , , , , , , , , Affiliations Expand Affiliations 1 China-Japan Friendship Hospital, Beijing, China. 2 Department of Endocrinology, The Second Affiliated Hospital, Chongqing Medical University

2020 EvidenceUpdates

12. Dapagliflozin (Forxiga): no place in type 1 diabetes

Dapagliflozin (Forxiga°) has no demonstrated efficacy with regard to the clinical complications of type 1 diabetes and it carries a risk of sometimes serious adverse effects. Dapagliflozin is one of the gliflozin group of hypoglycaemic drugs, which lower blood glucose levels by increasing excretion of glucose in the urine. In the European Union, the glifozins were first authorised for patients with type 2 diabetes. In that setting, their harm-benefit balance is unfavourable, mainly due to the risk (...) : "Dapagliflozin in type 2 diabetes: no advance in terms of cardiovascular complications" (January 2020) "Gliflozins: necrotising fasciitis of the perineum" Prescrire Int 2019; 28 (206): 181 "Empagliflozin (Jardiance°) in type 2 diabetes: no rush to use this drug" (June 2016) "Gliflozins: ketoacidosis" Prescrire Int 2016; 25 (169): 68 "Dapagliflozin. A hypoglycaemic drug causing disproportionate harm, especially to kidneys" Prescrire Int 2014; 23 (147): 61-64. Read more: All the subjects in Prescrire's

2020 Prescrire

13. Cardiovascular events and mortality in people with type 2 diabetes and multimorbidity: A real-world study of patients followed for up to 19 years Full Text available with Trip Pro

Cardiovascular events and mortality in people with type 2 diabetes and multimorbidity: A real-world study of patients followed for up to 19 years Cardiovascular events and mortality in people with type 2 diabetes and multimorbidity: A real-world study of patients followed for up to 19 years - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily (...) : 10.1111/dom.14218. Online ahead of print. Cardiovascular events and mortality in people with type 2 diabetes and multimorbidity: A real-world study of patients followed for up to 19 years , , , , Affiliations Expand Affiliations 1 Leicester Real World Evidence Unit, Diabetes Research Centre, Leicester General Hospital, University of Leicester, Leicester, UK. 2 Novo Nordisk Region Europe Pharmaceuticals A/S, København, Denmark. 3 Department of Diabetes Medicine, National Institute for Health Research

2020 EvidenceUpdates

14. Gastrointestinal adverse events with insulin glargine/lixisenatide fixed-ratio combination versus glucagon-like peptide-1 receptor agonists in people with type 2 diabetes mellitus: A network meta-analysis Full Text available with Trip Pro

Gastrointestinal adverse events with insulin glargine/lixisenatide fixed-ratio combination versus glucagon-like peptide-1 receptor agonists in people with type 2 diabetes mellitus: A network meta-analysis Gastrointestinal adverse events with insulin glargine/lixisenatide fixed-ratio combination versus glucagon-like peptide-1 receptor agonists in people with type 2 diabetes mellitus: A network meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage (...) Display options Format Share Permalink Copy Page navigation Diabetes Obes Metab Actions . 2020 Sep 29. doi: 10.1111/dom.14202. Online ahead of print. Gastrointestinal adverse events with insulin glargine/lixisenatide fixed-ratio combination versus glucagon-like peptide-1 receptor agonists in people with type 2 diabetes mellitus: A network meta-analysis , , , , , , , Affiliations Expand Affiliations 1 Centre of Research Excellence in Translating Nutritional Science to Good Health, University

2020 EvidenceUpdates

15. Insulin glargine/lixisenatide (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V

: November 2014 [online]. 11.2014 [Accessed: 11.03.2020]. URL: http://www.deutsche- diabetes-gesellschaft.de/fileadmin/Redakteur/Leitlinien/Evidenzbasierte_Leitlinien/dm- therapie-1aufl-vers4-lang.pdf. The full report (German version) is published under https://www.iqwig.de/en/projects-results/projects/drug-assessment/a20-38-insulin-glargine- lixisenatide-type-2-diabetes-mellitus-benefit-assessment-according-to-35a-social-code-book- v.13098.html. (...) Insulin glargine/lixisenatide (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Insulin glargin/Lixisenatid (Diabetes mellitus Typ 2) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 13 July 2020). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely

2020 Institute for Quality and Efficiency in Healthcare (IQWiG)

16. Oral semaglutide (Rybelsus) for the treatment of adults with insufficiently controlled type 2 diabetes mellitus

Oral semaglutide (Rybelsus) for the treatment of adults with insufficiently controlled type 2 diabetes mellitus Oral semaglutide (Rybelsus®) for the treatment of adults with insufficiently controlled type 2 diabetes mellitus | Report | National Health Care Institute You are here: Oral semaglutide (Rybelsus®) for the treatment of adults with insufficiently controlled type 2 diabetes mellitus Search within English part of National Health Care Institute Search Oral semaglutide (Rybelsus® (...) ) for the treatment of adults with insufficiently controlled type 2 diabetes mellitus Zorginstituut Nederland has completed its assessment, using the parallel procedure CBG-ZIN, whether oral semaglutide (Rybelsus®) is interchangeable with a product that is included in the medication reimbursement system (GVS). The Zorginstituut's advice is to include oral semaglutide (Rybelsus®) in Appendix 1B and Appendix 2 of the Health Insurance Regulation and to impose additional conditions. Registered indication Semaglutide

2020 National Health Care Institute (Zorginstituut Nederland)

17. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. Full Text available with Trip Pro

Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. The cardiovascular effects of ertugliflozin, an inhibitor of sodium-glucose cotransporter 2, have not been established.In a multicenter, double-blind trial, we randomly assigned patients with type 2 diabetes and atherosclerotic cardiovascular disease to receive 5 mg or 15 mg of ertugliflozin or placebo once daily. With the data from the two ertugliflozin dose groups pooled for analysis, the primary objective was to show (...) -mg dose of ertugliflozin and in 57 patients (2.1%) who received the 15-mg dose, as compared with 45 patients (1.6%) who received placebo.Among patients with type 2 diabetes and atherosclerotic cardiovascular disease, ertugliflozin was noninferior to placebo with respect to major adverse cardiovascular events. (Funded by Merck Sharp & Dohme and Pfizer; VERTIS CV ClinicalTrials.gov number, NCT01986881.).Copyright © 2020 Massachusetts Medical Society.

2020 NEJM

18. Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials

Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search (...) Lancet Diabetes Endocrinol Actions . 2020 Sep 21;S2213-8587(20)30313-2. doi: 10.1016/S2213-8587(20)30313-2. Online ahead of print. Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials , , , , , , , , Affiliations Expand Affiliations 1 KfH Kidney Center, Munich, Germany; Friedrich Alexander University of Erlangen-Nürnberg, Erlangen, Germany. Electronic address: johannes.mann

2020 EvidenceUpdates

19. Benefit/risk profile of dapagliflozin 5 mg in the DEPICT-1 and -2 trials in individuals with type 1 diabetes and body mass index >/=27 kg/m(2) Full Text available with Trip Pro

Benefit/risk profile of dapagliflozin 5 mg in the DEPICT-1 and -2 trials in individuals with type 1 diabetes and body mass index >/=27 kg/m(2) Benefit/risk profile of dapagliflozin 5 mg in the DEPICT-1 and -2 trials in individuals with type 1 diabetes and body mass index ≥27 kg/m 2 - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable (...) ahead of print. Benefit/risk profile of dapagliflozin 5 mg in the DEPICT-1 and -2 trials in individuals with type 1 diabetes and body mass index ≥27 kg/m 2 , , , , , , , , , Affiliations Expand Affiliations 1 Clinical and Experimental Endocrinology, UZ Gasthuisberg, University of Leuven, Leuven, Belgium. 2 State University of New York at Buffalo, Williamsville, New York, USA. 3 Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Centre Munich, University of Tübingen, Tübingen

2020 EvidenceUpdates

20. Effect of 6 Months of Flash Glucose Monitoring in Youth With Type 1 Diabetes and High-Risk Control: A Randomized Controlled Trial

. Effect of 6 Months of Flash Glucose Monitoring in Youth With Type 1 Diabetes and High-Risk Glycemic Control: A Randomized Controlled Trial , , , , , , , , , , Affiliations Expand Affiliations 1 Department of Women's and Children's Health, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand. 2 Centre for Biostatistics, Division of Health Sciences, University of Otago, Dunedin, New Zealand. 3 Department of Paediatrics and Child Health, University of Otago, Wellington, Wellington, New (...) Effect of 6 Months of Flash Glucose Monitoring in Youth With Type 1 Diabetes and High-Risk Control: A Randomized Controlled Trial Effect of 6 Months of Flash Glucose Monitoring in Youth With Type 1 Diabetes and High-Risk Glycemic Control: A Randomized Controlled Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19

2020 EvidenceUpdates